Biohaven Ltd. (BHVN NYSE) stock market data APIs
$14.1483
0.37(2.6%)
as of July 16, 2026
Try our APIs with
free plan!
Biohaven Ltd. Financial Data Overview
Price chart is built with
Anychart
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Prev. Close
14.1483
Open
14.5184
High
14.6439
Low
13.9903
52 wk Range
7.48-18.566
Market Cap
2 133 M
Shares Outstanding
151 M
EPS
-0.69
Beta
3.139
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Biohaven Ltd. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Biohaven Ltd. data using free add-ons & libraries
Get Biohaven Ltd. Fundamental Data
Biohaven Ltd. Fundamental data includes:
- Net Revenue:
- EBITDA: -607 192 128
- Earnings Per Share: -5
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-08
- EPS/Forecast: -1.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Biohaven Ltd. News
New
Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer
Bexorg, Inc. -Dr. Car brings more than 30 years of drug discovery experience to lead Bexorg's next phase of clinical translation; Dr. Fenn joins Bexorg to lead business development, asset strategy, a...
Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy?
Biohaven announced a series of scientific leadership changes, including the upcoming transition of Bruce Car, Ph.D., to Chief Innovation Officer, the promotion of David Pirman, Ph.D., to Executive Vic...
Biohaven Announces Scientific Leadership Transitions
David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on externa...
Biohaven (BHVN) Completes Enrollment in RISE3 Trial
Biohaven Ltd. (NYSE:BHVN) is one of the 10 Best Performing American Stocks in June 2026. On June 30, 2026, Biohaven Ltd. (NYSE:BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2...
Get Biohaven Ltd. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
